Physician profile
Sheena Jose
NPI 1710055389
$2,103.64
in general payments reported to CMS, 2019-2025
15 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $115 · 2021: $192 · 2022: $92.55 · 2023: $147 · 2024: $692 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,252.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $226.81 | 2021-2025 | |
| Boston Scientific Corporation | $125.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.22 | 2024-2025 | Trintellix |
| Pfizer INC. | $77.31 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.26 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $54.95 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $54.36 | 2025 | |
| Glaxosmithkline, LLC. | $36.81 | 2020-2022 | |
| Optos, INC. | $33.59 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $32.10 | 2025 | Rexulti |
| Novo Nordisk INC | $17.12 | 2025 | |
| Organon LLC | $17.04 | 2025 | Nexplanon |
| Exact Sciences Corporation | $15.84 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Jose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.